Large tumor suppressor kinase 2
LATS2 is one out of two Large tumour suppressor kinases (LATS1/2). LATS1/2 deletion leads to tumour regression through adaptive immune responses, and enhances tumour vaccine efficacy. LATS1/2 are part of the Hippo pathway, and LATS1/2-null tumor cells secrete nucleic-acid-rich extracellular vesicles, which induce a type I interferon response via the Toll-like receptors-MYD88/TRIF pathway1.
LATS2 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, Carson DA, Guan KL. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell. 2016 Dec 1;167(6):1525-39.